https://cambridgebrc.nihr.ac.uk/wp-content/uploads/2024/09/Cambridge_Biomedical_Research_Centre_Cytosponge1-1024x683-1.jpg
683
1024
Amanda
https://cambridgebrc.nihr.ac.uk/wp-content/uploads/2024/04/Cambridge_BRC_NIHR_logo.png
Amanda2024-11-28 11:06:032025-01-10 18:10:43Landmark ‘Pill-On-A-Thread’ cancer screening trial welcomes first participants
The NIHR Cambridge BRC is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust in partnership with the University of Cambridge. We are at the heart of the Cambridge Biomedical Campus, Europe’s largest health research area.
Contact Us
Cambridge Biomedical Research Centre
Box 277
Hills Road
Cambridge
CB2 0QQ
Tel: 01223 348490
Our Senior Investigator Award recognises outstanding research leaders, but questions about what the scheme represents can sometimes stop excellent candidates from applying.
To address this, Catherine Pope, Chair of the Senior Investigator Funding Committee, has written a blog
Sign up for a fascinating @NIHRresearch BRC: Oxford online talk on 21 July at 2pm on how managing high blood pressure during pregnancy and after giving birth, can help women reduce their long-term risk of stroke, heart disease and dementia. Sign up: https://events.teams.microsoft.com/event/4b000b0b-3314-462d-881e-739717c36d42@25d273c3-a851-4cfb-a239-e9048f989669
Want to find out more about undertaking commercial research at @CUH_NHS? Our half-day FREE workshop on Fri 17 July 08:30-13:00 at the Hexagon Centre on @CamBioCam is for CUH staff who want an overview of commercial research delivery. Book your spot now:
Join us this Friday (10 July) at 10am for the next in our PPI In Action webinar series. This time we’ll be looking at why and how the voices of young people are so critical in weight management research and service evaluation.
💬 Hear from speakers Dr Catherine Homer, Professor
☀️ June brought another big month of research across our Biomedical Research Centres - from life-extending cancer treatment to advances in heart disease, genetics, mental health and infectious disease.
🎥 Watch the video below for the highlights.
🔗 Read the full article:
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds